Trial · NCT02684786
A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
NCT02684786, Phase 1, Withdrawn, Mayo Clinic
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension. Trials, record NCT02684786. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02684786
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of Stellate Ganglion Block and / or Reserpine in Group 2 Pulmonary Hypertension
- NCT number
- NCT02684786
- Status
- Withdrawn
- Phases
- Phase 1
- Enrollment
- 0 participants, actual
- Lead sponsor
- Mayo Clinic
- Conditions
- Pulmonary Artery Hypertension
- Interventions
- reserpine, stellate ganglion block, lidocaine
- First posted
- 2016-02-18
- Last updated
- 2019-05-22
Source ClinicalTrials.gov
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | one month | Adverse events of interest are for stellate ganglion block: pulmonary edema, bradycardia requiring treatment, hypotension requiring treatment, arrhythmia, pneumothorax, hoarseness, dysphagia, globus, left upper extremity weakness. For reserpine, heart failure hospitalization, syncope, all cause hospitalization, bradycardia requiring treatment, hypotension requiring treatment, new arrhythmia, edema requiring an increase in diuretics, depression, lethargy, nasal stuffiness, dizziness, orthostatic hypotension, falls, nightmares, sexual dysfunction, anxiety, dyspepsia. Adverse events classed as serious: * Life threatening serious adverse events including acute coronary syndrome with active ischemia, fatal arrhythmias, myocardial infarction, acute kidney injury, cardiogenic shock, stroke, pulmonary embolization, arterial and/or venous thrombosis, systemic embolization, severe hypotension, respiratory failure and death * Prolonged hospitalization or rehospitalization |
| Secondary | Number of participants with successful stellate ganglion block | One hour | Stellate block: frequency of the occurrence of ptosis and conjunctival flushing. |
| Secondary | Effect of stellate ganglion block on heart rate | One hour | Heart rate before and after stellate ganglion block |
| Secondary | Change in 6 minute walk distance from one month of reserpine therapy | One month | Six minute walk distance, meters, baseline compared to one month |
| Secondary | Change in brain natriuretic peptide (BNP) from one month of reserpine therapy | One month | BNP, pg/ml, baseline compared to one month |
| Secondary | Change in Doppler derived mean pulmonary artery pressure from one month of reserpine therapy | One month | Mean pulmonary artery pressure estimate, mm Hg |
| Secondary | Change in blood pressure from one month of reserpine therapy | One month | Blood pressure, mm Hg, baseline versus one month |
| Secondary | Change in Minnesota Living with heart failure questionnaire from one month of reserpine therapy | One month | Minnesota Living with heart failure questionnaire aggregate score, baseline versus one month |
| Secondary | Hemodynamic effect of stellate ganglion block | One hour | Blood pressure, mm Hg, before and after stellate ganglion block |
| Secondary | Hemodynamic effect of stellate ganglion block | One hour | Pulmonary artery pressure, mm Hg, before and after stellate ganglion block |
1 to 10 of 14Source ClinicalTrials.gov
See all 14 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02684786
GET https://conductscience.org/api/trials/v1/NCT02684786/registered